Cargando…
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, includin...
Autores principales: | Franzetti, Marco, Pozzetti, Ugo, Carugati, Manuela, Pandolfo, Alessandro, Molteni, Chiara, Faccioli, Paolo, Castaldo, Gioacchino, Longoni, Ernesto, Ormas, Valentina, Iemoli, Enrico, Piconi, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228890/ https://www.ncbi.nlm.nih.gov/pubmed/32422376 http://dx.doi.org/10.1016/j.ijid.2020.05.050 |
Ejemplares similares
-
Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023) -
Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study
por: Maier, André, et al.
Publicado: (2015) -
The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats
por: Vallejo, Susana, et al.
Publicado: (2014) -
Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011) -
The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2021)